Arbutus Biopharma Co. (NASDAQ: ABUS) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $5.00 price target on the stock.
Arbutus Biopharma Co. (NASDAQ: ABUS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock.
Arbutus' Imdusiran Achieves Functional Cure in cHBV Patients when Combined with a Short Course of Interferon [Yahoo! Finance]
Arbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with Chronic Hepatitis B [Yahoo! Finance]
Arbutus’ Imdusiran Achieves Functional Cure in cHBV Patients when Combined with a Short Course of Interferon